Critical New HTA Developments in Europe: Challenges & Solutions
With Prof. Dr Lieven Annemans
Course Details
Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria should be used and how the HTA process should be conducted.
On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved.
In this one-day course you will learn how companies should optimise processes and criteria in this complex environment.
By participating, you will not only have the chance to learn from a true health economics and HTA expert, but also experience the unique opportunity to share experiences and engage in in-depth discussions with your international peers.
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
The different types of HTAs in Europe.
How to address the broad and evolving range of assessment criteria in Europe.
How to optimise clinical evidence generation for HTA bodies.
How to use Real-World Data for HTA purposes.
How to prepare for the Joint Clinical Assessment (JCA) in the EU.
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
| Welcome & Introductions (~15 min) |
| Definitions and Taxonomy of HTA (~1 h) |
|
| Optimising the Mix of Criteria: Challenges & Solutions (~1 h 30 min) |
|
| Generating Clinical Evidence: Challenges & Solutions (~45 min) |
|
| Lunch Break |
| The Increasing Need for Real World Data: Challenges & Solutions (~1 h 15 min) |
|
| Towards a Joint Clinical Assessment (JCA) in the EU: Challenges & Solutions (~1 h 30 min) |
|
| Summary & Final Discussion (~15 min) |
Prof. Dr Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.
Lieven has a unique profile: academic professor, past-president of ISPOR, author of Health economics for non-economists (Pelckmans Pro, 2018), trainer and consultant.
Highly respected for his vast international and cross-therapeutic experience, Lieven is a sought-after advisor and educator to health policy makers and the innovative healthcare industry.
Lieven has been on CELforPharma's faculty since 2009 and is always applauded by participants for his engaging and fun teaching style.
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
This course will be valuable to everyone for whom understanding the principles behind HTA, its usage and value is critical in their function, such as:
Market Access
Pricing & Reimbursement
Medical
Health Economics
Regulatory Affairs
Marketing
Would you like to receive a list of anonymised participant profiles from previous sessions?
Email Annelies Swaan
UPCOMING DATES & FORMATS - FEES
11 December 2025
Live online (CET timing)
Early bird € 1 470
(until 07/11/2025)
(Full fee € 1 670)
TIMING & LOCATION
Live Online (CET): Zoom sessions between 9 AM and 5 PM CET (Brussels, Amsterdam, Paris time).
Live Online (EST): Zoom sessions between 8 AM and 4 PM EST (Eastern Standard Time).
Face-to-Face: Held at the Crowne Plaza Brussels Airport (Da Vincilaan 4, 1831 Brussels), between 9 AM and 5 PM CET. Preferential hotel rates available for participants.
All practical details will be shared upon registration. For any questions, please contact Margherita Mutto or call +32 472 03 11 38 .
GROUP DISCOUNTS
Team discounts can be offered to 2 or more delegates from the same company.
Email Annelies Swaan, Director Business Operations, for more details.
HOW TO REGISTER
Click the green “Register” button on your preferred course session.
The registration wizard will guide you through the process.Alternatively, download the offline registration form and send the completed form to Annelies Swaan.
PAYMENT OPTIONS
Credit Card: You’ll receive a secure payment link with your invoice (no immediate payment required).
Bank Transfer: Details provided with your invoice.
For help with registration, email Annelies Swaan or contact her by phone at +32 486 98 52 49.
INCLUDED IN THE REGISTRATION FEE
Access to a highly interactive, small-group online course (max 20 participants)
Course materials in both digital and hard copy format
Certificate of attendance signed by the experts and CELforPharma
VAT INFORMATION
Prices exclude VAT. VAT application depends on course format and your location:
Face-to-Face in Belgium: 21% Belgian VAT applies
Live online courses & self-study programme: The applicable VAT depends on your invoicing address. Contact your local VAT office for refund procedures where applicable.
TRANSFER & CANCELLATION POLICY
Flexible Transfer
If a registrant is unable to attend the scheduled course, they can avoid any cancellation charges by providing a suitable replacement participant.
Alternatively, the registrant may transfer once, on a 'space-available' basis and at no extra cost, to another course of the same value held within one year of the original course date, provided this is done at least three weeks prior to the event.
Registration Cancellation
Less than 14 days prior to the course date: The registrant is liable to pay the full invoiced registration fee.
Between 15 and 30 days prior to the course date: The registrant is liable to pay 50% of the invoiced registration fee.
More than 30 days prior to the course date: The registrant is liable to pay a cancellation fee of € 450 per registrant.
If a registrant postpones their participation to a future course and subsequently cancels again, no refund will be issued for the registration fees.
The average Recommendation Score from participants of the last session was
9,0/10!
Testimonials from past participants:
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
The course and instructor were great. Lieven is clearly an expert in the field, with clear and articulate presentations. The interactions between attendees added to the experience, and I have gained valuable insights into the upcoming EU HTA changes. Highly recommended!
Novartis
Nick Riley, Senior Market Access Manager - Australia - June 2024
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
I got relevant information, it was refreshing also. The comparison of different countries' approaches and the excellent description of crucial parts of HTA were particularly useful. The experience from practice shared during the course enriched my understanding significantly.
Pharm-In
Dominik Grega, MA & HTA Manager - Slovakia - June 2024
People attending this course are typically also interested in:
Course Details
Dates & Locations
Upcoming Session
11 December 2025, Live online (CET timing)
Early bird € 1 470
(until 07/11/2025)
(Full fee € 1 670)
Prices are excl. VAT
Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria should be used and how the HTA process should be conducted.
On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved.
In this one-day course you will learn how companies should optimise processes and criteria in this complex environment.
By participating, you will not only have the chance to learn from a true health economics and HTA expert, but also experience the unique opportunity to share experiences and engage in in-depth discussions with your international peers.
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
The different types of HTAs in Europe.
How to address the broad and evolving range of assessment criteria in Europe.
How to optimise clinical evidence generation for HTA bodies.
How to use Real-World Data for HTA purposes.
How to prepare for the Joint Clinical Assessment (JCA) in the EU.
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
| Welcome & Introductions (~15 min) |
| Definitions and Taxonomy of HTA (~1 h) |
|
| Optimising the Mix of Criteria: Challenges & Solutions (~1 h 30 min) |
|
| Generating Clinical Evidence: Challenges & Solutions (~45 min) |
|
| Lunch Break |
| The Increasing Need for Real World Data: Challenges & Solutions (~1 h 15 min) |
|
| Towards a Joint Clinical Assessment (JCA) in the EU: Challenges & Solutions (~1 h 30 min) |
|
| Summary & Final Discussion (~15 min) |
Prof. Dr Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.
Lieven has a unique profile: academic professor, past-president of ISPOR, author of Health economics for non-economists (Pelckmans Pro, 2018), trainer and consultant.
Highly respected for his vast international and cross-therapeutic experience, Lieven is a sought-after advisor and educator to health policy makers and the innovative healthcare industry.
Lieven has been on CELforPharma's faculty since 2009 and is always applauded by participants for his engaging and fun teaching style.
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
This course will be valuable to everyone for whom understanding the principles behind HTA, its usage and value is critical in their function, such as:
Market Access
Pricing & Reimbursement
Medical
Health Economics
Regulatory Affairs
Marketing
Would you like to receive a list of anonymised participant profiles from previous sessions?
Email Annelies Swaan
UPCOMING DATES & FORMATS - FEES
11 December 2025
Live online (CET timing)
Early bird € 1 470
(until 07/11/2025)
(Full fee € 1 670)
TIMING & LOCATION
Live Online (CET): Zoom sessions between 9 AM and 5 PM CET (Brussels, Amsterdam, Paris time).
Live Online (EST): Zoom sessions between 8 AM and 4 PM EST (Eastern Standard Time).
Face-to-Face: Held at the Crowne Plaza Brussels Airport (Da Vincilaan 4, 1831 Brussels), between 9 AM and 5 PM CET. Preferential hotel rates available for participants.
All practical details will be shared upon registration. For any questions, please contact Margherita Mutto or call +32 472 03 11 38 .
GROUP DISCOUNTS
Team discounts can be offered to 2 or more delegates from the same company.
Email Annelies Swaan, Director Business Operations, for more details.
HOW TO REGISTER
Click the green “Register” button on your preferred course session.
The registration wizard will guide you through the process.Alternatively, download the offline registration form and send the completed form to Annelies Swaan.
PAYMENT OPTIONS
Credit Card: You’ll receive a secure payment link with your invoice (no immediate payment required).
Bank Transfer: Details provided with your invoice.
For help with registration, email Annelies Swaan or contact her by phone at +32 486 98 52 49.
INCLUDED IN THE REGISTRATION FEE
Access to a highly interactive, small-group online course (max 20 participants)
Course materials in both digital and hard copy format
Certificate of attendance signed by the experts and CELforPharma
VAT INFORMATION
Prices exclude VAT. VAT application depends on course format and your location:
Face-to-Face in Belgium: 21% Belgian VAT applies
Live online courses & self-study programme: The applicable VAT depends on your invoicing address. Contact your local VAT office for refund procedures where applicable.
TRANSFER & CANCELLATION POLICY
Flexible Transfer
If a registrant is unable to attend the scheduled course, they can avoid any cancellation charges by providing a suitable replacement participant.
Alternatively, the registrant may transfer once, on a 'space-available' basis and at no extra cost, to another course of the same value held within one year of the original course date, provided this is done at least three weeks prior to the event.
Registration Cancellation
Less than 14 days prior to the course date: The registrant is liable to pay the full invoiced registration fee.
Between 15 and 30 days prior to the course date: The registrant is liable to pay 50% of the invoiced registration fee.
More than 30 days prior to the course date: The registrant is liable to pay a cancellation fee of € 450 per registrant.
If a registrant postpones their participation to a future course and subsequently cancels again, no refund will be issued for the registration fees.
The average Recommendation Score from participants of the last session was
9,0/10!
Testimonials from past participants:
An excellent top-line overview of the practical application of health economics. The course covered a lot in a single day but remained digestible thanks to its clear format. I especially valued the discussion on current JCA developments. Peer input also added real value.
Kevin Veninga, Healthcare Communicator - The Netherlands - June 2025
Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr. Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic.
Merck
Laura Bauer, Senior Manager, Global Policy & External Affairs - Germany - June 2024
The course and instructor were great. Lieven is clearly an expert in the field, with clear and articulate presentations. The interactions between attendees added to the experience, and I have gained valuable insights into the upcoming EU HTA changes. Highly recommended!
Novartis
Nick Riley, Senior Market Access Manager - Australia - June 2024
Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching. I highly recommend this course!
Insuvia
Monika Staniulyte, Regulatory Affairs Team Lead - Lithuania - June 2024
I got relevant information, it was refreshing also. The comparison of different countries' approaches and the excellent description of crucial parts of HTA were particularly useful. The experience from practice shared during the course enriched my understanding significantly.
Pharm-In
Dominik Grega, MA & HTA Manager - Slovakia - June 2024
People attending this course are typically also interested in: